Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00081796|
Recruitment Status : Completed
First Posted : April 22, 2004
Last Update Posted : August 21, 2008
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer Metastases||Drug: larotaxel (RPR109881, XRP9881) Drug: capecitabine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||438 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks Versus Capecitabine (Xeloda) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients With Metastatic Breast Cancer Progressing After Taxanes and Anthracycline Therapy|
|Study Start Date :||April 2004|
|Actual Primary Completion Date :||September 2006|
|Actual Study Completion Date :||September 2006|
- Time to tumor progression.
- Overall survival.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00081796
|Study Director:||ICD CSD||Sanofi|